Biotech exposure from discovery to contract manufacturing, tiered by what stage the business is actually at.
Core — the theme IS a principal business todayGrowing — real operations, not yet the main businessAnnounced — committed plans or orders, little revenue yetMention-only — appears only as outlook language
Natco PharmaPharmaceuticalsAnnounced₹15,799 CrP/E 18.8 vs 28.5ROCE 15.9%
NATCO has committed strategic equity investments (e.g., US$ 8M in eGenesis for xenotransplantation, US$ 2M in Cellogen Therapeutics for CAR-T cell and gene therapies, US$ 1M each in Eyestem for cell therapy and Stero Therapeutics for rare diseases) and states an ambition to pursue cell and gene therapies, but this is not yet a revenue-generating business line for the company.
“We are strengthening our innovation pipeline through making strategic investments in New Chemical Entities, CAR-T cell therapies, gene-editing technologies and regenerative solutions, specifically targeting oncology, rare diseases, organ failure and retinal degeneration.”
Sai ParenteralsPharmaceuticalsAnnounced₹2,386 CrP/E 150.0 vs 28.5ROCE 1.4%
The company has been allotted land by the Government of Telangana for a future facility dedicated to oncology biosimilars and monoclonal antibodies, but no biologics manufacturing revenue exists yet.
“Beyond the current network, land has been allotted to us by the Government of Telangana for a future facility dedicated to oncology biosimilars and monoclonal antibodies, broadening the scope of our manufacturing capabilities for specialised therapies.”
How this list is built
Definition used: Discovers, develops or manufactures biologic drugs, vaccines, biosimilars, cell/gene therapies, or provides biotech CRO/CDMO services.Membership is extracted from each company’s newest annual report; every quote is validated against the report page before publishing, and core/growing tiers are confirmed by a second independent read (marked ). Companies whose reports our corpus hasn’t read yet simply aren’t listed — absence means unread, not “no exposure”.
MarketPing publishes facts, filings and measured history only — nothing on this page is investment advice, a recommendation or a rating.
